AnaptysBio, Inc. (ANAB)
55.83
-1.46
(-2.55%)
USD |
NASDAQ |
Aug 28, 15:10
AnaptysBio Market Cap : 1.621B for Aug. 28, 2026
Market Cap Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Market Cap Data
| Date | Value |
|---|---|
| August 27, 2026 | 1.663B |
| August 26, 2026 | 1.684B |
| August 25, 2026 | 1.695B |
| August 24, 2026 | 1.697B |
| August 21, 2026 | 1.676B |
| August 20, 2026 | 1.646B |
| August 19, 2026 | 1.720B |
| August 18, 2026 | 1.713B |
| August 17, 2026 | 1.733B |
| August 14, 2026 | 1.697B |
| August 13, 2026 | 1.626B |
| August 12, 2026 | 1.654B |
| August 11, 2026 | 1.680B |
| August 10, 2026 | 1.610B |
| August 07, 2026 | 1.643B |
| August 06, 2026 | 1.590B |
| August 05, 2026 | 1.596B |
| August 04, 2026 | 1.600B |
| August 03, 2026 | 1.558B |
| July 31, 2026 | 1.549B |
| July 30, 2026 | 1.598B |
| July 29, 2026 | 1.514B |
| July 28, 2026 | 1.513B |
| July 27, 2026 | 1.556B |
| July 24, 2026 | 1.572B |
| Date | Value |
|---|---|
| July 23, 2026 | 1.594B |
| July 22, 2026 | 1.527B |
| July 21, 2026 | 1.561B |
| July 20, 2026 | 1.460B |
| July 17, 2026 | 1.684B |
| July 16, 2026 | 1.572B |
| July 15, 2026 | 1.620B |
| July 14, 2026 | 1.815B |
| July 13, 2026 | 2.027B |
| July 10, 2026 | 1.927B |
| July 09, 2026 | 1.933B |
| July 08, 2026 | 1.897B |
| July 07, 2026 | 1.954B |
| July 06, 2026 | 1.809B |
| July 02, 2026 | 1.841B |
| July 01, 2026 | 1.899B |
| June 30, 2026 | 1.960B |
| June 29, 2026 | 1.915B |
| June 26, 2026 | 1.833B |
| June 25, 2026 | 1.733B |
| June 24, 2026 | 1.698B |
| June 23, 2026 | 1.725B |
| June 22, 2026 | 1.742B |
| June 18, 2026 | 1.670B |
| June 17, 2026 | 1.648B |
Market Capitalization Definition
Market Capitalization measures the total value of a company based on their stock price multiplied by the shares outstanding. This metric is important because it gives you an idea of the size of a company, and how the size has changed over time. When studying companies from a relative basis, it would make sense to compare companies that have a similar market capitalization because factors like market share, economies of scale, and business models would also be similar.
Market Cap Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Market Cap Benchmarks
| 4D Molecular Therapeutics, Inc. | 789.01M |
| Design Therapeutics, Inc. | 950.59M |
| Inhibrx Biosciences, Inc. | 1.840B |
| Agenus, Inc. | 328.14M |
| Amgen, Inc. | 232.97B |
Market Cap Related Metrics
| PS Ratio | 7.079 |
| Price to Book Value | 127.15 |
| Price to Free Cash Flow | 373.11 |
| Price | 55.83 |
| Earnings Yield | -1.94% |
| Operating PE Ratio | 40.32 |